Healthcare provider profile · identity verified

Manav Batra, MBBS

Endocrinology · WILLIAMSVILLE, NY · NPI 1396976403

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Ozempic	Semaglutide	674	153
Levothyroxine Sodium	Levothyroxine Sodium	589	147
Metformin Hcl	Metformin Hcl	443	102
Mounjaro	Tirzepatide	393	68
Atorvastatin Calcium	Atorvastatin Calcium	376	100
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	348	129
Trulicity	Dulaglutide	339	80
Pioglitazone Hcl	Pioglitazone Hcl	243	61
Jardiance	Empagliflozin	227	53
Humalog Kwikpen U-100	Insulin Lispro	220	97
Glipizide	Glipizide	218	54
Metformin Hcl Er	Metformin Hcl	193	56
Ultra-Fine Mini Pen Needle	Pen Needle, Diabetic	161	74
Novolog Flexpen	Insulin Aspart	109	45
Methimazole	Methimazole	104	33
Basaglar Kwikpen U-100	Insulin Glargine,hum.Rec.Anlog	102	36
Insulin Lispro Kwikpen U-100	Insulin Lispro	102	49
Lisinopril	Lisinopril	97	27
Hydrocortisone	Hydrocortisone	95	25
Synthroid	Levothyroxine Sodium	93	24
Amlodipine Besylate	Amlodipine Besylate	92	24
Nano 2nd Gen Pen Needle	Pen Needle, Diabetic	86	25
Glimepiride	Glimepiride	85	23
Rosuvastatin Calcium	Rosuvastatin Calcium	85	27
Omnipod 5 Dexg7g6 Pods (Gen 5)	Insulin Pump Cart,auto,bt,g6/7	71	14
Glipizide Er	Glipizide	60	23
Toujeo Solostar	Insulin Glargine,hum.Rec.Anlog	53	18
Toujeo Max Solostar	Insulin Glargine,hum.Rec.Anlog	52	18
Droplet Pen Needle	Pen Needle, Diabetic	48	30
Farxiga	Dapagliflozin Propanediol	48	suppressed
Tresiba Flextouch U-100	Insulin Degludec	46	24
Fenofibrate	Fenofibrate Nanocrystallized	44	suppressed
Ultra-Fine Short Pen Needle	Pen Needle, Diabetic	39	14
Humalog	Insulin Lispro	38	suppressed
Losartan Potassium	Losartan Potassium	38	13
Ezetimibe	Ezetimibe	36	13
Fiasp Flextouch	Insulin Aspart (Niacinamide)	35	18
Rybelsus	Semaglutide	33	11
Tresiba Flextouch U-200	Insulin Degludec	33	15
Lantus	Insulin Glargine,hum.Rec.Anlog	32	suppressed
Humulin N	Insulin Nph Human Isophane	30	suppressed
Pravastatin Sodium	Pravastatin Sodium	30	suppressed
Alendronate Sodium	Alendronate Sodium	29	suppressed
Metoprolol Tartrate	Metoprolol Tartrate	29	suppressed
Humulin R U-500 Kwikpen	Insulin Regular, Human	28	suppressed
Icosapent Ethyl	Icosapent Ethyl	28	suppressed
Novolog	Insulin Aspart	27	suppressed
Ultra-Fine Nano Pen Needle	Pen Needle, Diabetic	26	suppressed
Unifine Pentips	Pen Needle, Diabetic	26	suppressed
Januvia	Sitagliptin Phosphate	25	suppressed
Testosterone	Testosterone	25	12
Calcitriol	Calcitriol	24	suppressed
Cortef	Hydrocortisone	24	suppressed
Tradjenta	Linagliptin	24	suppressed
Insulin Lispro	Insulin Lispro	23	12
Testosterone Cypionate	Testosterone Cypionate	23	suppressed
Gabapentin	Gabapentin	22	suppressed
Metoprolol Succinate	Metoprolol Succinate	22	suppressed
Invokana	Canagliflozin	21	suppressed
Easy Comfort Pen Needle	Pen Needle, Diabetic	20	suppressed
Sure Comfort Pen Needle	Pen Needle, Diabetic	20	suppressed
Carvedilol	Carvedilol	19	suppressed
Hydrochlorothiazide	Hydrochlorothiazide	19	suppressed
Repaglinide	Repaglinide	19	suppressed
Cabergoline	Cabergoline	18	suppressed
Levemir Flexpen	Insulin Detemir	18	suppressed
Vascepa	Icosapent Ethyl	18	suppressed
Admelog Solostar	Insulin Lispro	17	suppressed
Irbesartan	Irbesartan	17	suppressed
Propylthiouracil	Propylthiouracil	16	suppressed
Spironolactone	Spironolactone	16	suppressed
Teriparatide	Teriparatide	16	suppressed
Victoza 3-Pak	Liraglutide	15	suppressed
Amitriptyline Hcl	Amitriptyline Hcl	13	suppressed
Humulin N Kwikpen	Insulin Nph Human Isophane	13	suppressed
Armour Thyroid	Thyroid,pork	12	suppressed
Ddavp	Desmopressin Acetate	12	suppressed
Humulin R	Insulin Regular, Human	12	suppressed
Omeprazole	Omeprazole	12	suppressed
Omnipod Dash Pods (Gen 4)	Insulin Pump Cart,cont Inf,bt	12	suppressed
Alcohol Prep Pads	Alcohol Antiseptic Pads	11	suppressed
Nateglinide	Nateglinide	11	suppressed
Simvastatin	Simvastatin	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error